Israel’s Elicio Therapeutics has published the results of a pre-clinical study of its ELI-005 protein subunit vaccine for Covid-19. It extended the life of coronavirus antibodies and may resolve the problem whereby patients who recover from the virus can be re-infected if later exposed to it.
Maintaining Covid-19 antibodies
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.